pegylated liposomal doxorubicin

P3, N=130, Not yet recruiting, AIDS Malignancy Consortium | Trial completion date: Dec 2029 --> Nov 2027 | Trial primary completion date: Mar 2028 --> Dec 2026

Herein, we demonstrate that pegylated liposomal doxorubicin (PLD) exhibits significantly enhanced antitumor and antimetastatic efficacy in obese breast tumor-bearing mice compared to normal controls...Conversely, supplementation with recombinant ApoE restores these effects in ApoE-deficient mice and potentiates PLD's antitumor efficacy. Collectively, our findings demonstrate obesity-induced ApoE as a pivotal regulator of the protein corona that actively enhances tumor-targeted delivery of PLD, which offers a rational strategy for engineering protein-corona-mediated tumor-targeted nanomedicines.

Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.

She received carboplatin/paclitaxel plus avelumab, followed by pegylated liposomal doxorubicin and weekly paclitaxel. This case illustrates that T-DXd can induce deep and durable remission in HER2-positive, dMMR metastatic serous endometrial cancer after multiple lines of therapy. It adds real-world evidence supporting further investigation of HER2-directed antibody-drug conjugates in gynaecologic malignancies, and underscores the need for confirmatory trials and refined biomarker-driven patient selection.

P2/3, N=260, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

P3, N=1080, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

In May 2025, the patient initiated intravenous chemotherapy consisting of pegylated liposomal doxorubicin and ifosfamide. This case highlights the importance of early integration of histopathological and molecular evaluation for progressive thyroid lesions. The co-occurrence of NF1 and BCORL1 mutations, along with TP53 and TERT promoter alterations, may underlie the tumor's aggressive biological behavior and supports the incorporation of molecular subtyping strategies in TLS management.

P1/2, N=29, Recruiting, TILT Biotherapeutics Ltd. | N=76 --> 29

P3, N=530, Recruiting, Genmab | Trial primary completion date: May 2027 --> Feb 2027

P3, N=1100, Not yet recruiting, AstraZeneca

P2, N=106, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Sep 2025

P3, N=466, Not yet recruiting, Incyte Corporation